Nattinee JantaratnotaiJames G. McLarnonThe University of British ColumbiaMahidol University2018-05-032018-05-032011-06-22Neuroscience Letters. Vol.497, No.2 (2011), 80-8418727972030439402-s2.0-79956336868https://repository.li.mahidol.ac.th/handle/20.500.14594/12785We have examined activation of purinergic P2Y 1 receptor-dependent Ca 2+ -signaling pathways in mediating C6 glioma cell migration. The administration of 2-methylthioadenosine 5'-diphosphate (2MeSADP), a selective agonist for P2Y 1 R, induced marked increases in patterns of glioma migration in both scratch wound and Boyden chamber assays. Antagonism of P2Y 1 R with either the broad spectrum purinergic blocker, pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS) or the specific P2Y 1 R antagonist, 2'-deoxy-N 6 -methyladenosine-3',5'-bisphosphate (MRS2179), significantly inhibited C6 cell migration. Calcium-sensitive spectrofluorometry showed 2MeSADP stimulation of glioma cells caused a biphasic change in intracellular Ca 2+ ([Ca 2+ ]i). The rapid transient phase was unchanged in Ca 2+ -free solution reflecting a [Ca 2+ ]i component due to intracellular stores release subsequent to activation of a metabotropic P2Y subtype receptor. The secondary prolonged phase of [Ca 2+ ]i was abolished in Ca 2+ -free solution or in glioma cells treated with the store-operated channel (SOC) blocker, SKF96365. Treatment of glioma with either MRS2179 or PPADS significantly attenuated both the rapid and prolonged phases of [Ca 2+ ]i. These results suggest critical roles for activation of P2Y 1 R in mediating glioma cell mobility and migration with changes in [Ca 2+ ]i contributing as a mechanistic link between activated receptor and functional response. Our findings suggest that pharmacological modulation of metabotropic P2Y 1 R-dependent signaling pathways may serve as a novel therapeutic procedure to slow glioma progression. © 2011 Elsevier Ireland Ltd.Mahidol UniversityNeuroscienceArticleSCOPUS10.1016/j.neulet.2011.04.034